PL3345907T3 - Związki pirazolo[3,4-d]pirymidynowe lub ich sole - Google Patents

Związki pirazolo[3,4-d]pirymidynowe lub ich sole

Info

Publication number
PL3345907T3
PL3345907T3 PL16841868T PL16841868T PL3345907T3 PL 3345907 T3 PL3345907 T3 PL 3345907T3 PL 16841868 T PL16841868 T PL 16841868T PL 16841868 T PL16841868 T PL 16841868T PL 3345907 T3 PL3345907 T3 PL 3345907T3
Authority
PL
Poland
Prior art keywords
pyrazolo
salts
pyrimidine compounds
pyrimidine
compounds
Prior art date
Application number
PL16841868T
Other languages
English (en)
Inventor
Yuichi Kawai
Hiroki Irie
Takeshi Sagara
Kazutaka Miyadera
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL3345907T3 publication Critical patent/PL3345907T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL16841868T 2015-09-01 2016-08-31 Związki pirazolo[3,4-d]pirymidynowe lub ich sole PL3345907T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015172354 2015-09-01
PCT/JP2016/075380 WO2017038838A1 (ja) 2015-09-01 2016-08-31 新規なピラゾロ[3,4-d]ピリミジン化合物又はその塩
EP16841868.9A EP3345907B1 (en) 2015-09-01 2016-08-31 Pyrazolo[3,4-d]pyrimidine compounds or salts thereof

Publications (1)

Publication Number Publication Date
PL3345907T3 true PL3345907T3 (pl) 2020-09-07

Family

ID=58188946

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16841868T PL3345907T3 (pl) 2015-09-01 2016-08-31 Związki pirazolo[3,4-d]pirymidynowe lub ich sole

Country Status (19)

Country Link
US (2) US9920060B2 (pl)
EP (1) EP3345907B1 (pl)
JP (1) JP6141568B1 (pl)
KR (1) KR102075886B1 (pl)
CN (1) CN108349981B (pl)
AU (1) AU2016317521B2 (pl)
BR (1) BR112018004175B8 (pl)
CA (1) CA2997051C (pl)
DK (1) DK3345907T3 (pl)
ES (1) ES2799520T3 (pl)
MX (1) MX373865B (pl)
MY (1) MY191938A (pl)
PH (1) PH12018500437B1 (pl)
PL (1) PL3345907T3 (pl)
PT (1) PT3345907T (pl)
RU (1) RU2705579C2 (pl)
SG (1) SG11201801365YA (pl)
TW (1) TWI659957B (pl)
WO (1) WO2017038838A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3092255A4 (en) 2014-01-10 2017-09-20 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating egfr expressing tumors
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
IL261107B2 (en) 2016-02-23 2023-11-01 Taiho Pharmaceutical Co Ltd A novel compressed pyrimidine compound or a salt thereof
KR102674711B1 (ko) * 2017-02-28 2024-06-12 다이호야쿠힌고교 가부시키가이샤 피라졸로[3,4-d]피리미딘 화합물을 사용한 항종양 효과 증강제
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
CN106967303A (zh) * 2017-05-02 2017-07-21 杭州福莱蒽特精细化工有限公司 一种艳色兰偶氮染料及其制备方法和应用
SG11202001212SA (en) 2017-08-21 2020-03-30 Taiho Pharmaceutical Co Ltd Fusion protein of dctn1 protein with ret protein
EP3845231B1 (en) * 2018-08-29 2025-01-01 Taiho Pharmaceutical Co., Ltd. Therapeutic agent containing pyrazolo[3,4-d]pyrimidine compound as active ingredient
WO2020045475A1 (ja) 2018-08-29 2020-03-05 大鵬薬品工業株式会社 ピラゾロ[3,4-d]ピリミジンの結晶
PT3909584T (pt) * 2019-01-11 2024-01-12 Taiho Pharmaceutical Co Ltd Composto de pirimidina ou um seu sal
CN113336760B (zh) * 2020-02-18 2022-11-04 深圳市塔吉瑞生物医药有限公司 取代的酰胺衍生物及其组合物及用途
CN111440138A (zh) * 2020-04-30 2020-07-24 中国林业科学研究院林产化学工业研究所 具有hdac抑制和抗肿瘤活性的新型漆酚基异羟肟酸衍生物的合成方法
US12492208B2 (en) 2020-07-15 2025-12-09 Taiho Pharmaceutical Co., Ltd. Crystal of pyrimidine compound
JP7373664B2 (ja) * 2020-07-15 2023-11-02 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
MX2023000693A (es) * 2020-07-15 2023-02-13 Taiho Pharmaceutical Co Ltd Inhibidor de egfr.
CA3196712A1 (en) 2020-09-23 2022-03-31 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
WO2022072634A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
WO2022072632A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
AU2021357081A1 (en) * 2020-10-05 2023-06-01 Dana-Farber Cancer Institute, Inc Potent and selective inhibitors of her2
TW202227063A (zh) 2020-10-09 2022-07-16 美商史考皮恩治療有限公司 治療癌症之方法
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
US20250161306A1 (en) * 2022-01-25 2025-05-22 KSQ Therapeutics, Inc. Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
CN114736207B (zh) * 2022-04-28 2023-03-31 武汉九州钰民医药科技有限公司 一种小分子her2抑制剂的制备工艺
EP4724151A1 (en) 2023-06-08 2026-04-15 Antares Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
CN121712773A (zh) 2023-06-08 2026-03-20 安塔列斯疗法股份有限公司 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000304A1 (en) * 2003-06-27 2005-01-06 Pfizer Products Inc. Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors
AR054816A1 (es) * 2005-07-13 2007-07-18 Banyu Pharma Co Ltd Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos
CN101336244B (zh) 2005-12-08 2011-11-30 雅培制药有限公司 用作蛋白激酶抑制剂的9元杂二环化合物
CN101007814A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯并六元杂环化合物及其在医药上的用途
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
SG10201508035TA (en) * 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
EA025496B1 (ru) * 2011-05-17 2016-12-30 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
EA201490265A1 (ru) * 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
MX351513B (es) 2012-01-19 2017-10-17 Taiho Pharmaceutical Co Ltd Compuesto de alquinilbenceno 3,5-disustituido y sales del mismo.
EP2947086B1 (en) * 2013-08-12 2018-01-03 Taiho Pharmaceutical Co., Ltd. Novel fused pyrimidine compound or salt thereof
EP3033079B1 (en) * 2013-08-12 2018-10-31 Pharmacyclics LLC Methods for the treatment of her2 amplified cancer

Also Published As

Publication number Publication date
MY191938A (en) 2022-07-19
PH12018500437A1 (en) 2018-08-29
SG11201801365YA (en) 2018-03-28
MX2018002520A (es) 2019-02-07
PH12018500437B1 (en) 2020-10-28
US20170217970A1 (en) 2017-08-03
CN108349981B (zh) 2021-03-30
BR112018004175B8 (pt) 2023-10-31
US20180201615A1 (en) 2018-07-19
TWI659957B (zh) 2019-05-21
KR102075886B1 (ko) 2020-02-11
EP3345907A1 (en) 2018-07-11
CN108349981A (zh) 2018-07-31
EP3345907B1 (en) 2020-04-22
MX373865B (es) 2020-03-26
US9920060B2 (en) 2018-03-20
JP6141568B1 (ja) 2017-06-07
ES2799520T3 (es) 2020-12-18
JPWO2017038838A1 (ja) 2017-08-31
RU2018111439A3 (pl) 2019-10-02
KR20180041757A (ko) 2018-04-24
PT3345907T (pt) 2020-06-23
CA2997051A1 (en) 2017-03-09
EP3345907A4 (en) 2019-03-20
AU2016317521B2 (en) 2019-02-14
US10329300B2 (en) 2019-06-25
RU2018111439A (ru) 2019-10-02
RU2705579C2 (ru) 2019-11-08
AU2016317521A1 (en) 2018-03-29
CA2997051C (en) 2020-03-24
WO2017038838A1 (ja) 2017-03-09
DK3345907T3 (da) 2020-06-22
HK1257146A1 (zh) 2019-10-11
TW201718592A (zh) 2017-06-01
BR112018004175A2 (pt) 2018-09-25
BR112018004175B1 (pt) 2023-07-25

Similar Documents

Publication Publication Date Title
SG11201801365YA (en) NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF
IL277576A (en) Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
IL265918B (en) Converted pyrazolo[1,5–a]pyridine compounds as ret kinase inhibitors
ZA201800771B (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
IL259169A (en) Novel pyrazolo pyrimidine derivatives
IL257306B (en) A compressed pyrimidine compound or a salt thereof
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
HUE056996T2 (hu) Pirido[3,4-d]pirimidin származék és gyógyszerészetileg elfogadható sója
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL262673A (en) A pyrazolo[5,1-a]pyrimidine compound
ZA201804871B (en) Process for preparing 7h-pyrrolo [2, 3-d] pyrimidine compounds
ZA201700823B (en) A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor
PT3330271T (pt) Composto de pirrolo[2,3-d]pirimidina ou sal do mesmo
HUE050298T2 (hu) Pirazolo[3,4-D]pirimidin vegyületek vagy annak sói
EP3227292A4 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
TH1601001194A (th) อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่
HK1240222A1 (en) 4h-pyrido[1,2-a]pyrimidin-4-one compounds
AU2014904868A0 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS